Toward adoption of health risk assessment in population-based and clinical scenarios

HRA IN CATALONIA: 2011-2020

The 2011-2015 Catalan Health Plan(13) fostered key achievements in digital health transformation, the progressive implementation of person-centred integrated care services and the adoption of an initial population-based HRA strategy. This transitory HRA strategy was based on the commercial solution “Clinical Risk Groups” (CRG)(14) from vendor 3M™ and oriented toward modelling healthcare costs for resource allocation and benchmarking.

This initial HRA strategy laid the groundwork for a population-based risk stratification program with a case-finding approach focused on preventing adverse health events, managing high-risk chronic patients, and early detecting end-of-life patients(15,16). This HRA approach acknowledged the close relationship between frailty and multimorbidity while recognizing their distinct nature as independent risk factors. Additionally, it introduced specific scales for the evaluation of each factor individually. The clinical complexity level was assigned based on multimorbidity scoring, transitively using CRGs, and the clinical judgment of primary care physicians. Complex patients were classified into two groups: complex chronic patients (CCP), approximately 4% of the population, and advanced chronic patients (ACP), representing approximately 1% of the population with limited life expectancy. Specific community-based management plans, aiming at integrating health and social care, were defined for these two categories of patients(15). An overall description of the care model for people with frailty and multimorbidity in Catalonia, tested during the 2011-2015 Health Plan, has been recently reported in (17).

The need for refining the assessment of the multimorbidity burden triggered the creation of the Adjusted Morbidity Groups (AMG)(18,19), a new morbidity grouper that reflects patients’ disease burden in terms of the number and complexity of concomitant disorders through a disease-specific weighting deduced from statistical analysis based on mortality and the utilisation of healthcare resources. The AMG tool was jointly launched in 2015 by the Spanish Health Ministry and the Catalan public health commissioner (CatSalut). A significant achievement was the development of a dashboard to monitor the population’s multimorbidity burden and the use of healthcare known as Modules for Monitoring Quality Indicators (“Moduls pel Seguiment d’Indicadors de Qualitat”, MSIQ)(20), which generates and displays customised key performance indicators (KPIs) with aggregated data to inform health policy decisions, benchmarking, and governance. On the clinical side, the AMG scoring of the patient is currently displayed in the workstation of the primary care physicians and the shared clinical history(21) as a support tool in the clinical setting.

During the 2016-2020 Catalan Health Plan(22), the utilisation of AMG for HRA purposes was validated in different regions of Spain, covering a population of approximately 38 million citizens and showing good transferability in all cases(23). This period witnessed three significant advancements in Catalonia’s HRA strategy:

1. The execution of several studies testing the contribution of the AMG in different HRA settings, such as the identified risk factors during the SARS-CoV-2 pandemic(24,25), the refinement of tools for resources allocation(26–29), the analysis of the effect of the multimorbidity burden in patients with chronic obstructive pulmonary disease (COPD)(30), and assessing the use of AMG in complex clinical predictive models for short-term clinical outcomes predictions after hospital discharge(4,5).

2. The creation of the Catalan Health Information System Master Plan published in 2019(31) established the basis for the transformation to a new digital-health paradigm based on a knowledge-driven platform and adopting the Open-EHR standard as a reference.

3. The development and internal validation of the Queralt indices(32,33) to characterise the complexity of hospitalisation episodes, combining information on the principal discharge diagnosis, pre-existing comorbidities, in-hospital complications and all the procedures performed during hospitalisation.

Figure 1 depicts the information required from NAs to use the AMG, the outputs obtained, and the key uses of AMG.

• Download figure
• Open in new tab

Figure 1

Panel A - AMG input: Required input variables to compute AMG; Panel B – AMG output: Output variables of the AMG algorithm. *Binary markers (presence/absence) of 15 chronic conditions (from left to right): diabetes mellitus, heart failure, chronic obstructive pulmonary disease, high blood pressure, depression, HIV/AIDS, chronic ischemic heart disease, stroke, chronic kidney disease, cirrhosis, osteoporosis, arthrosis, arthritis, dementia, chronic pain; Panel C– Health Risk Assessment based on AMG: The AMG scoring allows for three key actions: Classification: The population is categorised into specific groups based on their morbidity statuses, such as healthy, pregnancy and labour, acute disease, chronic disease in 1-4 systems, or active neoplasia, which are also divided into five degrees of severity. Stratification: Each individual can be assigned a complexity score that reflects the care needs that people may have based on their health problems. Identification: Individuals with specific major chronic health problems can be identified, which helps track people with more complex care needs.

Marche

Implementation achievements - 1) dynamic regional dataset preparation merging information from different existing data sources, 2) data cleaning and automatization of the generation of the regional dataset, 3) elaboration and analysis of the risk assessment pyramid at regional level demonstrating association between GMA scoring and local use of resources, 4) preparation of the logistics for local sustainability of the setting; and 5) design of the regional dashboard to facilitate regional health governance. The technicalities of the implementation and the assessment of the implementation process will be reported in a forthcoming paper.

Sustainability Action Plan - 1) to complete the integration of the tool into the regional IT infrastructure, adding further healthcare databases and defining supportive actions to improve the quality and completeness of healthcare data. 2) to implement the dashboard in computational, technical, and graphical terms, adding maps aimed to visualize healthcare services adjusted to social-health care planning regulations and integrating it in the regional IT infrastructure. 3) to promote the use of the HRA tools by regional and clinical managers and share our experience for the discussions on the secondary use of health data.

Estonia

Implementation achievements – 1) Generating a protocol, already approved by the local Ethics committee for a pragmatic randomized control trial (n= 1000), to test effectiveness and value generation of an integrated care intervention to prevent hospitalizations targeting community-based patients with high-risk of admissions and enhancing transitional care post-discharge to reduce early readmissions (PAIK 2022-2025). 2) AMG will be used as inclusion criteria and to modulate the characteristics of the intervention and the Queralt indices will be employed to characterize hospitalization episodes contributing to personalize transitional care after discharge.

Sustainability Action Plan - 1) to successfully execute the PAIK 2022-2025 project using AMG and Queralt indices as risk assessment tools.2) to generate sound proposals for innovative reimbursement modalities.3) to achieve country-wide scalability of risk prediction approaches based on AMG and Queralt.4) to initiate a debate on the scalability of integrated care services involving innovative reimbursement modalities in Estonia.

Evolution of the Catalan oGP during JADECARE

The 2020 Catalan Health Information System Master Plan has sparked ongoing technological innovations that offer significant opportunities in predictive modelling aiming at supporting clinical decision-making for healthcare professionals and provide patients with decision support tools to empower self-management(39–41). Also, specific initiatives have been launched to enhance transitional care and reduce early readmissions after hospital discharge(4,5). Moreover, efforts are devoted to the practicalities of adoption of such predictive modelling tools in real-world settings, involving: 1) training and continuous evaluation of clinical decision support systems embedded into integrated care services, 2) pragmatic use of implementation science tools to foster engagement of health professionals, and 3) ethical and regulatory aspects including refinement of the regional PADRIS program(42) for secondary use of health data.

In Catalonia, research, and innovation in HRA are currently focused on two target areas. Firstly, to address unmet needs associated with enhanced predictive modelling considering four potential sources of variables: 1) clinical information, 2) registry data with a population health approach, 3) patients’ self-reported information (PROMs and PREMs) and self-monitoring data, and 4) biomedical research data, as defined in (1). A key learning from the different studies done using the AMG algorithm since 2015 is that multimorbidity has a central explanatory role in health risk assessment, more than classical variables like age, which prompts the inclusion of the AMG scoring as a fix covariate in multisource predictive modelling.

A second field of research interest is the potential evolutions of AMG incorporating information on patients’ disease trajectories(43,44). Although these novel computational developments are still far from being applicable in clinical settings, they present exciting prospects or precision medicine in patients with NCDs.

Overarching analysis

The case practice identifies the process of transference and adoption of the AMG algorithm and a site-tailored dashboard using aggregated data as the two key components necessary for establishing fundamental HRA functionalities.

While Marche adopted a population-health approach considering the use of healthcare resources from the entire geographical area, Viljandi Hospital in Estonia implemented a more limited regional population-medicine orientation with a single hospital as a local integrator and lead in a regional health improvement initiative. As depicted in Figure 2, the differences in terms of sources and composition of input data had significant impacts on the distribution of AMG scoring among Catalonia (Figure 2 - Panel 1, population-health data from all healthcare tiers), Marche (Figure 2 - Panel 2, population-health data with poor representation of primary care) and Viljandi Hospital (Figure 2 - Panel 3, population-medicine approach based on hospital information). Accordingly, population-health databases, as those used in Marche region, must comprise information on disease diagnostics from all individuals within the region, gathered from various tiers of the healthcare system (e.g. primary care, community, hospital, etc.). It is expected to find a significant fraction of the healthy population and cases with transitory health problems, both concentrated in the youngest fraction of the population. The remaining population is expected to suffer at least chronicity and many of them to develop multimorbidity; among them is expected to find a small fraction of complex chronic patients.

On the other hand, if the analysis is conducted following a population medicine approach, as done in Viljandi, the sample should be representative of the population treated at the hospital during the period assessed, both in terms of demographic parameters and the clinical profiles of the patients. In light of this, a highly biased population is expected to be older than the hospital’s catching area average. Also, a substantial increase in the frequency of patients experiencing mainly acute and chronic conditions is anticipated.

Consequently, the composition of the input datasets plays a crucial role in modulating both purposes and suitability of adopting HRA strategies. In the current case practice, Marche’s approach was adequate to cover health policy aspects, resources allocation, benchmarking, and governance at the regional level, even though limitations due to GDPR constraints at the Italian level should be acknowledged. In contrast, the HRA orientation adopted by Viljandi Hospital was beneficial in the design process of the PAIK2 protocol (2023–2025), aiming at generating evidence of the effectiveness of an integrated care intervention to prevent hospitalisations in high-risk patients and transitional care. It is of note that the process of developing the case practice in the two sites has generated knowledge and skills that will be needed to elaborate future site-customised comprehensive HRA strategies, as described in the case of Catalonia.

In summary, the essential maturity requirements for sustainable HRA strategies are: 1) to achieve solid political commitment at the regional/country level fostering necessary interactions, top-down and bottom-up, among key stakeholders; 2) to have an essential digital maturity at the site level to satisfactorily pass the feasibility analysis; 3) to overcome potential limitations due to local application of GDPR; 4) to use highly applicable implementation science tools fostering engagement of all stakeholders, health policy managers and health professionals, during the process elaboration and deployment of the local HRA strategy; and 5) to develop/adopt a regulatory framework for secondary use of health data, needed for business intelligence and the elaboration of computational modelling for clinical applications. Table 2 depicts the steps identified during the transference process to define a roadmap for adopting site-customised HRA strategies.

Moreover, using the HRA tools described in the case practice as open-source software and articulating public-private collaborations supporting productive interactions and networking among sites are essential to speed up transferability and large-scale adoption of HRA strategies at the European level.